Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy

被引：1
|
作者：
Eng, C.
Bendell, J. C.
Bessudo, A.
Gabrail, N. Y.
Diamond, J.
Pande, A. U.
Gorbatchevsky, I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Pacific Oncol Hematol Associates, Encinitas, CA USA
[4] Gabrail Canc Ctr, Canton, OH USA
[5] Daiichi Sankyo, Edison, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527
引用
收藏
页数：1
相关论文
共 26 条
  • [21] A BLINDED PLACEBO (P) CONTROLLED PHASE 1/2 DOSE ESCALATION STUDY (DES) OF BRIVANIB (B), AN ORAL SELECTIVE DUAL INHIBITOR OF FGF AND VEGF SIGNALING, IN COMBINATION WITH CETUXIMAB (C) AND IRINOTECAN (I) IN PATIENTS (PTS) WITH KRAS WILD TYPE (KWT) ADVANCED OR METASTATIC COLORECTAL CANCER (AMCRC): SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) FINDINGS
    Park, Y. S.
    El-Khoueiry, A.
    Cubillo, A.
    Pfeifer, P.
    Chacon, M.
    Amadori, D.
    Fokstuen, T.
    Chemidlin, J. M.
    Kollia, G.
    Nuyten, D. S. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 199 - 199
  • [22] NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
    Jacobs, Samuel A.
    George, Thomas J.
    Kolevska, Tatjana
    Wade, James Lloyd
    Zera, Richard
    Buchschacher, Gary L.
    Al Baghdadi, Tareq
    Shipstone, Asheesh
    Lin, Daniel
    Yothers, Greg
    Pogue-Geile, Katherine L.
    Huggins-Puhalla, Shannon Leigh
    Allegra, Carmen Joseph
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).
    Tabernero, Josep
    Braga, Nicoletta
    Davis, Craig
    Gollerkeri, Ashwin
    Pierce, Kristen
    Suzuki, Mie
    Vermette, Jennifer
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).
    Cervantes-Ruiperez, Andres
    Markman, Ben
    Siena, Salvatore
    Pericay, Carles
    Aprile, Giuseppe
    Bridgewater, John A.
    Cubillo, Antonio
    Waterston, Ashita Marie
    Garcia-Carbonero, Rocio
    Kozloff, Mark
    McKendrick, Joseph James
    Samuel, Leslie M.
    Perez-Fidalgo, Jose Alejandro
    Strickland, Andrew H.
    Bencardino, Katia
    Moya, Irene
    Lutrino, Stefania Eufemia
    Mancao, Christoph
    Manenti, Luigi
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
    Yoshioka, H.
    Azuma, K.
    Yamamoto, N.
    Takahashi, T.
    Nishio, M.
    Katakami, N.
    Ahn, M. J.
    Hirashima, T.
    Maemondo, M.
    Kim, S. W.
    Kurosaki, M.
    Akinaga, S.
    Park, K.
    Tsai, C. M.
    Tamura, T.
    Mitsudomi, T.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2066 - 2072
  • [26] NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or n plus cetuximab (C) in patients (pts) with "quadruple wild-type (WT)" (KRAS/NRAS/BRAF/PIK3CA WT) metastatic colorectal cancer (mCRC) based on HER2 status-Amplified (amp), non-amplified (non-amp), WT, or mutated (mt).
    Jacobs, Samuel A.
    Lee, James J.
    George, Thomas J.
    Yothers, Greg
    Kolevska, Tatjana
    Yost, Kathleen J.
    Wade, James Lloyd
    Buchschacher, Gary L.
    Stella, Philip J.
    Shipstone, Asheesh
    Pogue-Geile, Katherine L.
    Srinivasan, Ashok
    Lucas, Peter C.
    Allegra, Carmen Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
123